World's Best Scientists 2026 revealed!
Daniel J. DeAngelo

Daniel J. DeAngelo

D-Index & Metrics

Medicine

D-Index
98
Citations
43079
World Ranking
8818
National Ranking
4543

Overview

Daniel J. DeAngelo is affiliated with Harvard University in the United States and has a substantial body of work primarily in the field of medicine. Their research focuses on hematology, oncology, genetics, immunology, and public health, environmental and occupational health.

The scientist has contributed extensively to topics related to acute lymphoblastic leukemia research, acute myeloid leukemia research, chronic myeloid leukemia treatments, CAR-T cell therapy research, mast cells and histamine, chronic lymphocytic leukemia research, and eosinophilic disorders and syndromes.

DeAngelo's frequent co-authors include:

  • Richard M. Stone
  • Marlise R. Luskin
  • Jacqueline S. Garcia
  • Eric S. Winer
  • Martha Wadleigh

The scientist's work has been published predominantly in:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Journal of Clinical Oncology
  • Blood Advances
  • Leukemia

Some of the recent publications include:

  • "KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study", 2021, The Lancet
  • "Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology", 2020, Journal of the National Comprehensive Cancer Network
  • "Prediction of Risk for Myeloid Malignancy in Clonal Hematopoiesis", 2023, NEJM Evidence
  • "Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology", 2021, Journal of the National Comprehensive Cancer Network
  • "Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms", 2021, Cell stem cell

Their academic contributions highlight a focus on clinical practices, disease risk predictions, and cellular-level research on blood cancers and related disorders.

Best Publications

  • A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome

    Jan Cools;Jan Cools;Daniel J. DeAngelo;Jason Gotlib;Elizabeth H. Stover

  • MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.

    Yana Pikman;Benjamin H Lee;Thomas Mercher;Elizabeth McDowell

  • Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

    Eytan M. Stein;Eytan M. Stein;Courtney D. DiNardo;Daniel A. Pollyea;Amir T. Fathi

  • Differentiation and reversal of malignant changes in colon cancer through PPARgamma.

    Pasha Sarraf;Elisabetta Mueller;Daniel Jones;Frederick J. King

  • Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.

    Hagop M. Kantarjian;Daniel J. DeAngelo;Matthias Stelljes;Giovanni Martinelli

  • A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

    Jorge E. Cortes;D. W. Kim;J. Pinilla-Ibarz;P. Le Coutre

  • Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.

    John Koreth;Richard Schlenk;Kenneth J. Kopecky;Sumihisa Honda

  • Acute myeloid leukemia ontogeny is defined by distinct somatic mutations

    R. Coleman Lindsley;Brenton G. Mar;Emanuele Mazzola;Peter V. Grauman

  • Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412

    Richard M. Stone;Daniel J. DeAngelo;Virginia Klimek;Ilene Galinsky

  • The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

    Camille Abboud;Ellin Berman;Adam Cohen

  • Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia

    Rongqing Pan;Leah J. Hogdal;Juliana M. Benito;Donna Bucci

  • Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3

    Thomas Fischer;Richard M. Stone;Daniel J. DeAngelo;Ilene Galinsky

  • Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy

    Triona Ni Chonghaile;Kristopher A. Sarosiek;Thanh Trang Vo;Jeremy A. Ryan

  • KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study

    Bijal D Shah;Armin Ghobadi;Olalekan O Oluwole;Aaron C Logan

  • Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

    Jorge E. Cortes;Dong Wook Kim;Javier Pinilla-Ibarz;Philipp D. le Coutre

  • Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

    Martha Wadleigh;Paul G. Richardson;David Zahrieh;Stephanie J. Lee

  • Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia

    Akinori Yoda;Yuka Yoda;Sabina Chiaretti;Michal Bar-Natan

  • Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms.

    Ofir Wolach;Ofir Wolach;Ofir Wolach;Rob S. Sellar;Rob S. Sellar;Rob S. Sellar;Kimberly Martinod;Deya Cherpokova

  • Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age.

    Edwin P Alyea;Edwin P Alyea;Haesook T Kim;Haesook T Kim;Vincent T Ho;Vincent T Ho;Corey Cutler;Corey Cutler

  • Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study.

    Eytan M. Stein;Courtney Denton Dinardo;Daniel Aaron Pollyea;Amir Tahmasb Fathi

Frequent Co-Authors

Richard Stone
Richard Stone Harvard University
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
David P. Steensma
David P. Steensma Harvard University
Donna Neuberg
Donna Neuberg Harvard University
Jorge E. Cortes
Jorge E. Cortes Augusta University
Michael W. Deininger
Michael W. Deininger University of Utah
Susan O'Brien
Susan O'Brien University of California, Irvine
Moshe Talpaz
Moshe Talpaz University of Michigan–Ann Arbor
Robert J. Soiffer
Robert J. Soiffer Harvard University
Timothy P. Hughes
Timothy P. Hughes South Australian Health and Medical Research Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine opens doors to a variety of related pathways and online degrees. If you are a registered nurse seeking to boost your credentials or increase earning potential, pursuing one of the rn to bsn cheapest programs is an affordable option. These programs are flexible and allow you to keep working as you study.

For those with a non-nursing background but interested in nursing, direct entry msn online pathways offer a fast track into advanced nursing roles without needing a traditional BSN. Admission requirements can vary, but some students prioritize finding easy nursing programs to get into to accelerate their entry into the healthcare workforce.

Not all healthcare careers require a medical degree. Medical billing and coding is a growing field with online training options—and you may be wondering, can you get financial aid for medical billing and coding? Financial assistance is often available, making it easier for students to enter this essential healthcare support career.

Best Scientists Citing Daniel J. DeAngelo

Trending Scientists